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Perspectives
Background
The introduction of antiretroviral 
therapy (ART) in the early 1990s 
profoundly changed the face of HIV 
infection by improving survival rates 
[1]. But ART has equal potential 
for prevention, since it reduces the 
probability of HIV transmission from 
an infected person to their sexual 
partner(s). Although there have been 
no randomized controlled clinical trials 
on the subject, antiretroviral drugs 
are currently used in clinical practice 
for post-exposure prophylaxis after 
inadvertent occupational exposure 
(based on the results of a case control 
study [2]) or after sexual exposure 
to the virus [3]. Pre- and post-
exposure prophylaxis (PrEP and PEP, 
respectively) have been used successfully 
to interrupt transmission of HIV from 
infected mothers to their babies [4].
Investigators at the United States 
Centers for Disease Control and 
Prevention have conducted a series of 
studies in rhesus macaques to explore 
antiretroviral prophylaxis. First, they 
developed a rectal inoculation model 
using concentrations of simian HIV 
(SHIV) representative of human 
exposure [5]. Using this model, the 
investigators showed that tenofovir 
disoproxil fumarate (TDF, a nucleotide 
analogue reverse transcriptase 
inhibitor) delayed, but did not prevent, 
acquisition of SHIV in these animals 
(seven out of eight animals infected 
over 14 weeks) [6]. A new study in 
this issue of PLoS Medicine by Walid 
Heneine and colleagues [7] extends 
earlier observations and will certainly 
affect the direction of human clinical 
trials and public health policy. 
The Results
In the new study, macaques were 
exposed to weekly rectal virus 
challenges for up to 14 weeks. The 
authors compared infections observed 
in 18 untreated macaques to infections 
in macaques that received a variety 
of antiretroviral PrEP regimens 
containing the nucleotide reverse 
transcriptase inhibitor emtricitabine 
(FTC) alone or in combination with 
TDF. With subcutaneous FTC alone 
(at a human-equivalent dose), four 
out of six animals became infected. 
With a combination of oral FTC and 
TDF at a dose equivalent to Truvada 
(FTC 200 mg + TDF 300 mg) in 
humans, two out of six animals became 
infected. With subcutaneous FTC and 
a supratherapeutic subcutaneous dose 
of tenofovir (given either daily or in 
a two-dose regimen before and after 
exposure), complete protection from 
infection was observed (none of the 12 
animals became infected). 
For animals that became infected 
during treatment, the investigators 
noted that infection was delayed, and 
all animals had blunted acute viremia, 
suggesting the possibility of reduced 
immune damage during acute HIV 
infection [8]. Resistance to FTC was 
observed in two out of six animals that 
failed therapy.
The Implications
These and earlier animal studies have 
provided the basis for human clinical 
trials with PrEP. The observation 
of FTC resistance during therapy 
emphasizes the risk of PrEP to the 
individual and the community. PrEP 
continued in the face of unrecognized 
infection might be expected to 
promote replication of a resistant 
variant, which could be transmitted 
widely [9]. Tenofovir and FTC 
resistance are common in populations 
receiving ART, including in sub-
Saharan Africa [10]. In addition, clade 
C HIV (predominant in sub-Saharan 
Africa) may be more susceptible to 
the evolution of a tenofovir resistance 
mutation (the K65R mutation) [11]. 
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This Perspective discusses the 
following new study published in PLoS
Medicine:
García-Lerma JG, Otten RA, Qari 
SH, Jackson E, Cong M, et al. (2008) 
Prevention of rectal SHIV transmission 
in macaques by daily or intermittent 
prophylaxis with emtricitabine 
and tenofovir. PLoS Med 5(2): e28. 
doi:10.1371/journal.pmed.0050028
Using a repeat-exposure macaque 
model, Walid Heneine and colleagues 
ﬁnd that pre-exposure prophylaxis 
with combination antiretroviral drugs 
provides protection against rectal 
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Strengths and Limitations of the 
New Study
This new report [7] represents the 
culmination of a series of recent 
studies speciﬁcally designed to guide 
and inform human clinical PrEP trials 
[5,6]. In addition, the new study shows 
protection from SHIV by intermittent 
dosing with tenofovir and FTC, a 
regimen that is closer to true PrEP than 
continuous daily dosing. 
The study had four weaknesses. 
First, it included only small numbers 
of animals. Second, nine out of the 18 
controls used were historical in nature. 
Third, FTC and tenofovir doses chosen 
as human-equivalent were based 
on ﬁrst-dose pharmacokinetics in a 
limited number of animals, and they 
represent higher drug exposures than 
seen in humans (FTC and tenofovir 
areas under the concentration-
time curves in macaques were 
approximately 30% and 40% higher, 
respectively, than exposures in humans 
[12]). In addition, intracellular 
pharmacokinetics of the active agents 
also differ between macaques and 
humans [13–15]. Finally, complete 
protection from HIV acquisition was 
only observed with a subcutaneous 
tenofovir dose that provided 
concentrations greater than can be 
achieved with oral therapy [16]. 
The Future
These results highlight an exciting 
and potentially important use of ART 
to prevent sexual transmission of 
HIV [3], and offer further support 
for human clinical trials in progress 
or planned. Optimistic modeling 
experiments suggest an important role 
for PrEP in HIV prevention [17]. But 
the application of PrEP highlights a 
unique tension between prevention and 
treatment; widespread usage of ART for 
prevention in communities where ART 
for treatment is still being rationed 
might cause conﬂict [18]. Also, 
PrEP has the potential to accelerate 
transmitted drug resistance [9], thereby 
limiting the utility of drugs critical to 
combination ART. Human PrEP trials 
must address these concerns. One 
PrEP safety trial has been completed 
in women at high risk of acquiring 
HIV in Africa [19]; other current trials 
designed to measure PrEP safety and 
efﬁcacy are summarized in Table 1. 
These PrEP trials will shine a light on 
the potential of ART for prevention, 
and help physicians to think more 
broadly about the public health 
implications of these life-saving drugs.  
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